Get the Stockscreener App
5.68
4.54%
-0.27
After Hours:
5.66
-0.02
-0.35%
Recursion Pharmaceuticals Inc stock is traded at $5.68, with a volume of 17.90M.
It is down -4.54% in the last 24 hours and up +10.72% over the past month.
Recursion Pharmaceuticals Inc is a clinical-stage biotechnology company. The company is decoding biology by integrating technological innovations across biology, chemistry, automation, data science, and engineering, with the goal of radically improving the lives of patients and industrializing drug discovery.
See More
Previous Close:
$5.95
Open:
$5.62
24h Volume:
17.90M
Relative Volume:
0.66
Market Cap:
$2.27B
Revenue:
$64.60M
Net Income/Loss:
$-377.75M
P/E Ratio:
-3.6645
EPS:
-1.55
Net Cash Flow:
$-335.64M
1W Performance:
-12.48%
1M Performance:
+10.72%
6M Performance:
-21.55%
1Y Performance:
-22.62%
1-Day Range:
$5.575
$5.82
1-Week Range:
$5.575
$6.685
52-Week Range:
$3.79
$12.36
Recursion Pharmaceuticals Inc Stock (RXRX) Company Profile
Name
Recursion Pharmaceuticals Inc
Sector
Industry
Phone
(385) 269-0203
Address
41S RIO GRANDE STREET, SALT LAKE CITY
Compare RXRX with other stocks
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
RXRX
Recursion Pharmaceuticals Inc
|
5.68 | 2.58B | 64.60M | -377.75M | -335.64M | -1.55 |
|
VRTX
Vertex Pharmaceuticals Inc
|
462.13 | 117.32B | 11.10B | -988.90M | -1.26B | -3.92 |
|
REGN
Regeneron Pharmaceuticals Inc
|
558.87 | 58.89B | 14.09B | 4.50B | 2.96B | 39.28 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
401.80 | 51.14B | 2.35B | -269.70M | -75.39M | -2.09 |
|
ARGX
Argen X Se Adr
|
673.80 | 41.02B | 2.58B | 1.06B | -1.28B | 16.33 |
|
ONC
Beone Medicines Ltd Adr
|
299.01 | 32.59B | 3.81B | -644.79M | -669.77M | -6.24 |
Recursion Pharmaceuticals Inc Stock (RXRX) Upgrades & Downgrades
| Date | Action | Analyst | Rating Change |
|---|---|---|---|
| Jul-03-25 | Resumed | Morgan Stanley | Equal-Weight |
| May-22-23 | Initiated | Morgan Stanley | Equal-Weight |
| Mar-16-23 | Initiated | Needham | Buy |
| Sep-16-22 | Initiated | KeyBanc Capital Markets | Overweight |
| Apr-18-22 | Downgrade | BofA Securities | Buy → Neutral |
| Mar-04-22 | Downgrade | SVB Leerink | Outperform → Mkt Perform |
| Sep-21-21 | Initiated | Berenberg | Buy |
| May-11-21 | Initiated | BofA Securities | Buy |
| May-11-21 | Initiated | Goldman | Neutral |
| May-11-21 | Initiated | JP Morgan | Neutral |
| May-11-21 | Initiated | KeyBanc Capital Markets | Overweight |
| May-11-21 | Initiated | SVB Leerink | Outperform |
View All
Recursion Pharmaceuticals Inc Stock (RXRX) Latest News
Should I hold or sell Recursion Pharmaceuticals Inc. stock in 2025Daily Trading Alerts For Every Investor - jammulinksnews.com
What are the latest earnings results for Recursion Pharmaceuticals Inc.Market Forecast Alerts Backed By Experts - jammulinksnews.com
When is Recursion Pharmaceuticals Inc. stock expected to show significant growthFinancial News Outlook For 2025 - jammulinksnews.com
What catalysts could drive Recursion Pharmaceuticals Inc. stock higher in 2025Financial News Data Feed With Proven Results - jammulinksnews.com
What is the risk reward ratio of investing in Recursion Pharmaceuticals Inc. stockSwing Trade Growth Plan With High Returns - jammulinksnews.com
How does Recursion Pharmaceuticals Inc. generate profit in a changing economyBreakout Stocks Ideas For 2025 - jammulinksnews.com
Recursion Pharmaceuticals (RXRX) Registers a Bigger Fall Than the Market: Important Facts to Note - Yahoo Finance
Drug Discovery Platforms Market Size Expected to Reach USD 635.45 Million by 2034 - GlobeNewswire Inc.
The Median Retirement Savings for American Households Is $87,000. Here Are 3 Incredible Stocks to Buy Now and Hold for Decades. - AOL.com
Why Recursion Pharmaceuticals (RXRX) Dipped More Than Broader Market Today - Yahoo Finance
Recursion's Q2 2025 Earnings: A TechBio Powerhouse Poised for Breakthroughs and Synergy-Driven Growth - AInvest
Recursion to Report Second Quarter 2025 Business Updates and Financial Results on August 5th - FinancialContent
Short Covering May Lift Recursion Pharmaceuticals Inc. in Near TermWeekly Growth Stock Entry Point Alerts Highlighted - metal.it
Why Recursion Pharmaceuticals Stock Got Mashed on Monday - AOL.com
Why Recursion Pharmaceuticals (RXRX) Soared On Friday - MSN
Recursion Pharmaceuticals Inc. Approaches Psychological Resistance LevelBreakout Entry Signal Confirmation Tool Used - metal.it
Tempus AI (TEM) vs. Recursion (RXRX): Which AI Biotech Stock Is Better? - 24/7 Wall St.
What institutional investors are buying Recursion Pharmaceuticals Inc. stockMaximize profits with strategic stock selection - jammulinksnews.com
What is the dividend policy of Recursion Pharmaceuticals Inc. stockMaximize gains with timely market signals - jammulinksnews.com
How volatile is Recursion Pharmaceuticals Inc. stock compared to the marketUnlock powerful stock screening techniques - jammulinksnews.com
Palantir, Nvidia & Tempus AI: The Future of Medicine in 2025 - AInvest
Big Pharma's Disruption: AI-Powered Palantir, Tempus, and Recursion Change the Game - AInvest
Palantir, Nvidia & Tempus AI Could Be Pharma ETF Darlings That Don't Make Pills - Benzinga
RXRX Stock Surges: What Awaits Next? - timothysykes.com
Recursion Pharmaceuticals Inc. Stock Analysis and ForecastAccelerated financial growth - PrintWeekIndia
Recursion Pharmaceuticals call volume above normal and directionally bullish - TipRanks
How Palantir, Tempus, Nvidia-Backed Recursion Are Disrupting Big Pharma - Benzinga
RXRX vs. RLAY: Which Precision Biotech Stock is a Better Bet Now? - Yahoo Finance
Is Recursion Pharmaceuticals Inc. a good long term investmentAccelerated capital growth - PrintWeekIndia
What drives Recursion Pharmaceuticals Inc. stock priceStrongest growth potential - Autocar Professional
How high can Recursion Pharmaceuticals Inc. stock price go in 2025Rapid return acceleration - jammulinksnews.com
Recursion Pharmaceuticals (RXRX) Soars 5.8%: Is Further Upside Left in the Stock? - MSN
What analysts say about Recursion Pharmaceuticals Inc. stockSignificant capital appreciation - PrintWeekIndia
RXRX September 5th Options Begin Trading - Nasdaq
Recursion Pharmaceuticals Experiences 10.7% Stock Price Surge Amid Strong Investor Interest - AInvest
Recursion Pharmaceuticals (RXRX) Stock Drops Despite Market Gains: Important Facts to Note - MSN
Recursion Pharmaceuticals (RXRX) Jumps 9.6% Ahead of Q2 Earnings - MSN
Can Recent Pipeline Expansion Efforts Offset RXRX's Earlier Losses? - The Globe and Mail
Recursion Pharmaceuticals Trading Volume Drops 52.75% to $23.7 Million, Ranks 464th in Market - AInvest
Recursion Pharmaceuticals Acquires Full Rights to REV102, Potential Oral Therapy for Rare Bone Disorder Hypophosphatasia - MSN
Recursion Pharmaceuticals Inc Stock (RXRX) Financials Data
Revenue
Net Income
Cash Flow
EPS
0.93%
0.15%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):